Astrazeneca (AZN) Capital Expenditures (2009 - 2026)

Astrazeneca's Capital Expenditures history runs 17 years deep, the most recent figure standing at -$547.0 million for Q1 2026.

• In Q1 2026, Capital Expenditures fell 27.51% year-over-year to -$547.0 million; the TTM figure through Mar 2026 stood at $2.7 billion (up 40.79% YoY), while the FY2025 annual figure was $2.8 billion, up 46.05% from the prior year.
• Capital Expenditures was -$547.0 million for Q1 2026 at Astrazeneca, down from $4.6 billion in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $4.6 billion in Q4 2025 to a low of -$686.0 million in Q3 2025.
• Historically, Capital Expenditures has averaged $246.0 million across 5 years, with a median of -$382.0 million in 2024.
• Biggest YoY gain for Capital Expenditures was 45.99% in 2025; the steepest drop was 72.51% in 2025.
• A 5-year view of Capital Expenditures shows it stood at -$253.0 million in 2022, then dropped by 6.72% to -$270.0 million in 2023, then surged by 1262.96% to $3.1 billion in 2024, then surged by 45.99% to $4.6 billion in 2025, then plunged by 111.93% to -$547.0 million in 2026.
• The last three Capital Expenditures figures came in at -$547.0 million (Q1 2026), $4.6 billion (Q4 2025), and -$686.0 million (Q3 2025), per Business Quant data.